Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Mechthild Jonas

2PUBLICATIONS

22CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (2)

Sort by Publication Date:

|Sep 29, 2023

Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity.

Ryan A Heiser, Anthony T Cao, Weiping Zeng

|Aug 24, 2023

SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.

Robert P Lyon, Mechthild Jonas, Christopher Frantz

Pageof 1

Frequent Collaborators

2 joint publications

Esther S Trueblood

1 joint publications

Robert P Lyon

1 joint publications

Christopher Frantz

1 joint publications

Roma Yumul

1 joint publications

Lori Westendorf

1 joint publications

Christopher J Hale

1 joint publications

Jackie L Stilwell

1 joint publications

Narayana Yeddula

1 joint publications

Katie M Snead

1 joint publications

Vineet Kumar

Frequent Collaborators

2 joint publications

Esther S Trueblood

1 joint publications

Robert P Lyon

1 joint publications

Christopher Frantz

1 joint publications

Roma Yumul

Top Related Videos

<em>In Vivo</em> Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

<em>In Vivo</em> Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on : Sep 23, 2021

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

See more related videos

Top Related Videos

<em>In Vivo</em> Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

<em>In Vivo</em> Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on : Sep 23, 2021

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

See more related videos